Try Now>> See today’s best-performing stocks on TipRanks >> Read More on SWTX: SpringWorks Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

09:46 EST SpringWorks Therapeutics (SWTX) trading halted, volatility trading pause Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and ...

Goldman Sachs initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target The company is developing siRNA therapies and its lead asset, zerlasiran, targets Lp(a ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s shares closed last Friday at $0.75. Leverage the ...

Goldman Sachs analyst Richard Law initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target Published first on TheFly – the ultimate source for real-time ...

Oppenheimer analyst Jeff Jones downgraded Pliant Therapeutics (PLRX) to Perform from Outperform without a price target after the company announced a voluntary pause to the enrollment, and dosing ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report). The company’s shares closed last Friday at $7.79. Leverage the ...

Hoth Therapeutics (HOTH) announced its collaboration with OnTargetx R&D to advance research for its cancer-fighting therapeutic, HT-KIT. This immunohistochemistry study, conducted in partnership ...

Citi downgraded Pliant Therapeutics (PLRX) to Neutral from Buy with a price target of $4, down from $40, after the company announced it has voluntarily paused enrollment and dosing for the BEACON ...

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report) today and set a price target of $71.00. The company’s shares closed last Friday ...

JPMorgan downgraded Pliant Therapeutics (PLRX) to Neutral from Overweight without a price target after the company announced a voluntary pause to the enrollment, and dosing, of its Phase 2b BEACON ...

Canaccord analyst Edward Nash downgraded Pliant Therapeutics (PLRX) to Hold from Buy with a price target of $4, down from $43, after the company paused enrollment and dosing in the ongoing Phase ...